Price T Rowe Associates Inc Kronos Bio, Inc. Transaction History

Price T Rowe Associates Inc

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$1.44 - $3.44 $10,935 - $26,123	-7,594 Reduced 4.44%	163,592 $265,000
Q3 2022 Nov 14, 2022	SELL	$3.35 - $5.55 $764,218 - $1.27 Million	-228,125 Reduced 57.13%	171,186 $575,000
Q2 2022 Aug 15, 2022	SELL	$3.12 - $7.52 $1,728 - $4,166	-554 Reduced 0.14%	399,311 $1.45 Million
Q1 2022 May 16, 2022	SELL	$6.26 - $14.42 $7.1 Million - $16.3 Million	-1,133,697 Reduced 73.93%	399,865 $2.89 Million
Q4 2021 Feb 14, 2022	SELL	$11.35 - $21.18 $2.72 Million - $5.08 Million	-239,621 Reduced 13.51%	1,533,562 $20.8 Million
Q3 2021 Nov 15, 2021	BUY	$18.17 - $24.7 $100,153 - $136,146	5,512 Added 0.31%	1,773,183 $37.2 Million
Q2 2021 Aug 16, 2021	SELL	$20.08 - $29.02 $6.82 Million - $9.86 Million	-339,837 Reduced 16.13%	1,767,671 $42.3 Million
Q1 2021 May 17, 2021	SELL	$27.0 - $32.48 $163,890 - $197,153	-6,070 Reduced 0.29%	2,107,508 $60.3 Million
Q4 2020 Feb 16, 2021	BUY	$26.68 - $38.23 $56.4 Million - $80.8 Million	2,113,578 New	2,113,578 $61.7 Million

19.8M

9.3K

100

Ticker KRON
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,769,100
Market Cap $53.9M
Description
Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company's product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidate is entospletinib (ENTO), is an orally...

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

Stay updated on Price T Rowe Associates Inc with notifications on news.